TY - JOUR
T1 - Injectable colloidal gold for use in intrafractional 2D image-guided radiation therapy
AU - Jølck, Rasmus Irming
AU - Rydhög, Jonas S.
AU - Christensen, Anders Nymark
AU - Hansen, Anders Elias
AU - Bruun, Linda Maria
AU - Schaarup-Jensen, Henrik
AU - von Wenck, Asger
AU - Børresen, Betina
AU - Kristensen, Annemarie Thuri
AU - Clausen, Mads Hartvig
AU - Kjær, Andreas
AU - Conradsen, Knut
AU - Larsen, Rasmus
AU - Munck af Rosenschöld, Per Martin
AU - Andresen, Thomas L
N1 - © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - In the western world, approximately 50% of all cancer patients receive radiotherapy alone or in combination with surgery or chemotherapy. Image-guided radiotherapy (IGRT) has in recent years been introduced to enhance precision of the delivery of radiation dose to tumor tissue. Fiducial markers are often inserted inside the tumor to improve IGRT precision and to enable monitoring of the tumor position during radiation therapy. In the present article, a liquid fiducial tissue marker is presented, which can be injected into tumor tissue using thin and flexible needles. The liquid fiducial has high radio-opacity, which allows for marker-based image guidance in 2D and 3D X-ray imaging during radiation therapy. This is achieved by surface-engineering gold nanoparticles to be highly compatible with a carbohydrate-based gelation matrix. The new fiducial marker is investigated in mice where they are highly biocompatible and stable after implantation. To investigate the clinical potential, a study is conducted in a canine cancer patient with spontaneous developed solid tumor in which the marker is successfully injected and used to align and image-guide radiation treatment of the canine patient. It is concluded that the new fiducial marker has highly interesting properties that warrant investigations in cancer patients. First liquid fiducial marker for image-guided radiation therapy is visible in both 2D- and 3D X-ray-based imaging. Doping sucrose acetate isobutyrate with poly(N-isopropyl acrylamide)-coated gold nanoparticles results in a liquid fiducial marker (nanogel) with a contrast level >1000 HU. External radiation therapy is delivered by depositing the nanogel intratumorally in a canine patient with spontaneous cancer, providing evidence of the clinical potential of the developed nanogel.
AB - In the western world, approximately 50% of all cancer patients receive radiotherapy alone or in combination with surgery or chemotherapy. Image-guided radiotherapy (IGRT) has in recent years been introduced to enhance precision of the delivery of radiation dose to tumor tissue. Fiducial markers are often inserted inside the tumor to improve IGRT precision and to enable monitoring of the tumor position during radiation therapy. In the present article, a liquid fiducial tissue marker is presented, which can be injected into tumor tissue using thin and flexible needles. The liquid fiducial has high radio-opacity, which allows for marker-based image guidance in 2D and 3D X-ray imaging during radiation therapy. This is achieved by surface-engineering gold nanoparticles to be highly compatible with a carbohydrate-based gelation matrix. The new fiducial marker is investigated in mice where they are highly biocompatible and stable after implantation. To investigate the clinical potential, a study is conducted in a canine cancer patient with spontaneous developed solid tumor in which the marker is successfully injected and used to align and image-guide radiation treatment of the canine patient. It is concluded that the new fiducial marker has highly interesting properties that warrant investigations in cancer patients. First liquid fiducial marker for image-guided radiation therapy is visible in both 2D- and 3D X-ray-based imaging. Doping sucrose acetate isobutyrate with poly(N-isopropyl acrylamide)-coated gold nanoparticles results in a liquid fiducial marker (nanogel) with a contrast level >1000 HU. External radiation therapy is delivered by depositing the nanogel intratumorally in a canine patient with spontaneous cancer, providing evidence of the clinical potential of the developed nanogel.
U2 - 10.1002/adhm.201400651
DO - 10.1002/adhm.201400651
M3 - Journal article
C2 - 25607532
SN - 2192-2640
VL - 4
SP - 856
EP - 863
JO - Advanced healthcare materials
JF - Advanced healthcare materials
IS - 6
ER -
